| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/16/2013 | WO2013070401A1 Camalexin as a treatment for prostate cancer |
| 05/16/2013 | WO2013070236A1 Methods and compositions for treating hemorrhoids while providing local anesthetic and anti-inflammatory effects |
| 05/16/2013 | WO2013070118A1 (3k,4k,58)-4-acylamino-5-amino-3-(1-ethyl-propoxy)-cyclohex-1-ene carboxylic acids, esters thereof and method of use |
| 05/16/2013 | WO2013070107A1 5h-dibenzo[b,e][1,4]diazepine derivatives and use thereof |
| 05/16/2013 | WO2013070030A1 Composition containing 3-dodecanoyloxy-2-isobutyryloxy-4-methylpentanoic acid as active ingredient |
| 05/16/2013 | WO2013070018A1 Composition comprising carnosic acid or derivative thereof |
| 05/16/2013 | WO2013069897A1 Stabilised sustained-release preparation of sarpogrelate |
| 05/16/2013 | WO2013069861A1 Pharmaceutical composition for preventing and treating neuropathic pain containing gaba nerve cells differentiated and induced by treating adipose tissue-derived stem cells with cbm-1078 as active ingredient |
| 05/16/2013 | WO2013069780A1 Viral infection preventive |
| 05/16/2013 | WO2013069771A1 Anthranilic acid derivative and noxious organism control agent |
| 05/16/2013 | WO2013069765A1 Nitrogenated heterocyclic compound |
| 05/16/2013 | WO2013069764A1 Method for ingesting creatine composition, creatine composition for use in said ingestion method, and creatine-containing medicinal agent and food each produced using said creatine composition |
| 05/16/2013 | WO2013069611A1 Rna having immunomodulating activity |
| 05/16/2013 | WO2013069404A1 Therapeutic agent for joint diseases |
| 05/16/2013 | WO2013069339A1 Puncture pain alleviating external preparation |
| 05/16/2013 | WO2013069297A1 7-{(3s,4s)-3-[(cyclopropylamino)methyl]-4-fluoropyrrolidine-1-yl}-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid crystal |
| 05/16/2013 | WO2013069027A1 Processes for the preparation of cabazitaxel involving c(7) -oh and c(13) -oh silylation or just c(7) -oh silylation |
| 05/16/2013 | WO2013069016A2 Long lasting drug formulations |
| 05/16/2013 | WO2013068993A2 Tyrosine isomers as therapeutic agents |
| 05/16/2013 | WO2013068979A2 Cosmetic composition comprising at least one alkoxysilane |
| 05/16/2013 | WO2013068972A1 Nadph oxidase 4 inhibitors and use thereof |
| 05/16/2013 | WO2013068971A2 Cosmetic composition comprising a modified alpha-alkoxysilane |
| 05/16/2013 | WO2013068969A2 Cosmetic composition comprising an alpha-alkoxysilane obtained from a polyamine |
| 05/16/2013 | WO2013068968A2 Cosmetic composition comprising an alpha-alkoxysilane obtained from an epoxide |
| 05/16/2013 | WO2013068967A2 Cosmetic composition comprising an alpha-alkoxysilane obtained from an acrylate |
| 05/16/2013 | WO2013068966A2 Cosmetic composition comprising an urea or amide based alpha-alkoxysilane |
| 05/16/2013 | WO2013068948A1 2-oxo-oxazolidin-3,5-diyl antibiotic derivatives |
| 05/16/2013 | WO2013068935A1 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-yl)picolinamide derivatives as orexin receptor antagonists |
| 05/16/2013 | WO2013068909A1 N-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide for the treatment of chronic myelogenous leukemia |
| 05/16/2013 | WO2013068879A2 Infant formula with high sn-2 palmitate and oligofructose |
| 05/16/2013 | WO2013068876A1 Methods and compositions for treating ocular allergy |
| 05/16/2013 | WO2013068875A1 2-thiopyrimidinones |
| 05/16/2013 | WO2013068836A1 A ddr1 antagonist or an inhibitor of ddr1 gene expression for use in the prevention or treatment of crescentic glomerulonephritis |
| 05/16/2013 | WO2013068785A1 Indanone and indandione derivatives and heterocyclic analogs |
| 05/16/2013 | WO2013068774A1 Therapeutic combination of memantine and baclofen and pharmaceutical composition containing them |
| 05/16/2013 | WO2013068769A1 Pharmaceutical compounds |
| 05/16/2013 | WO2013068755A1 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use |
| 05/16/2013 | WO2013068704A1 Phytoecdysones for use in weight stabilisation after a weight-loss diet |
| 05/16/2013 | WO2013068626A1 Pentacyclic triterpenes for use in the prevention or treatment of acute or subacute myocarditis |
| 05/16/2013 | WO2013068621A1 Use of a chemical compound derived from a 1,2,3,5-tetrasubstituted pyrole in the preparation of a drug for use in treating inflammatory diseases involving processes of cellular apoptosis |
| 05/16/2013 | WO2013068600A1 Medicament for the treatment of cardiac disease |
| 05/16/2013 | WO2013068592A1 Inhibitors of cystathionine beta synthase to reduce the neurotoxic overproduction of endogenous hydrogen sulfide |
| 05/16/2013 | WO2013068565A2 Melatonin-based solutions and powders for their preparation |
| 05/16/2013 | WO2013068554A1 New cyclohexylamine derivatives having beta 2 adrenergic agonist and m3 muscarinic antagonist activities |
| 05/16/2013 | WO2013068552A1 NEW CYCLOHEXYLAMINE DERIVATIVES HAVING β2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES |
| 05/16/2013 | WO2013068551A1 Disubstituted triazine dimers for treatment and/or prevention of infectious diseases |
| 05/16/2013 | WO2013068489A1 Heterocyclic carboxamides useful as inhibitors of phosphodiesterase type 10a |
| 05/16/2013 | WO2013068470A1 Inhibitors of phosphodiesterase type 10a |
| 05/16/2013 | WO2013068467A1 Substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with a co-containing group as vanilloid receptor ligands |
| 05/16/2013 | WO2013068464A1 Substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with an so2-containing group as vanilloid receptor ligands |
| 05/16/2013 | WO2013068463A1 Substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with an n-cyclic group as vanilloid receptor ligands |
| 05/16/2013 | WO2013068462A1 Substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with an n-containing group as vanilloid receptor ligands |
| 05/16/2013 | WO2013068461A1 Substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with an o-containing group as vanilloid receptor ligands |
| 05/16/2013 | WO2013068458A1 Therapeutically active thiazolo-pyrimidine derivatives |
| 05/16/2013 | WO2013068441A1 Compounds for the modulation of smn2 splicing |
| 05/16/2013 | WO2013068439A1 4-amino-5-oxo-7,8-dihydropyrimido[5, 4 -f] [1, 4] oxazepine compounds as dgat1 inhibitors |
| 05/16/2013 | WO2013068438A1 Purine derivatives for the treatment of viral infections |
| 05/16/2013 | WO2013068431A1 New treatment for neurodegenerative diseases |
| 05/16/2013 | WO2013068371A1 Soft chewable dosage form compositions of cannabinoid receptor type 1 (cb-1) antagonists |
| 05/16/2013 | WO2013068348A1 Lna oligomers for improvement in hepatic function |
| 05/16/2013 | WO2013068328A1 Bicyclo [2.2.2] octan-1-ylcarboxylic acid compounds as dgat-1 inhibitors |
| 05/16/2013 | WO2013068322A1 Alkenyl naphthylacetic acids for treating respiratory disorders |
| 05/16/2013 | WO2013068306A1 [1, 2, 3] triazolo [4, 5 -d] pyrimidine derivatives as agonists of the cannabinoid receptor 2 |
| 05/16/2013 | WO2013068014A1 Pharmaceutical compositions comprising lubricants for preventing or reducing aseptic loosening in a subject |
| 05/16/2013 | WO2013067882A1 Water-soluble vitamin e derivative modified fat-soluble anti-cancer drug compound and formulation, preparation method and use thereof |
| 05/16/2013 | WO2013067881A1 Water-soluble vitamin e derivative-modified amphiphilic anticancer medicament compound and preparation, method for preparing the compound, and application thereof |
| 05/16/2013 | WO2013067878A1 Ertapenem sodium crystal and preparation method thereof |
| 05/16/2013 | WO2013067769A1 Liquid composition of anti-hepatitis b virus |
| 05/16/2013 | WO2013067767A1 Polyethylene glycol-amino acid oligopeptide-irinotecan drug conjugate and drug composition thereof |
| 05/16/2013 | WO2013067749A1 Use of (-)-epigallocatechin gallate |
| 05/16/2013 | WO2013067710A1 Nampt inhibitors |
| 05/16/2013 | WO2013067682A1 A hydrocolloid composition and an article containing the same |
| 05/16/2013 | WO2013067639A1 Use of rank/rankl antagonists for treating neuromuscular disorders, genetic myopathies and/or non genetic myopathies and/or for regulating skeletal and cardiac muscle disuse, diseases and aging |
| 05/16/2013 | WO2013067612A1 Pharmaceutical composition for the preparation of a drug for treating neuropathic pain, chronic degenerative disease-related pain and post-operative pain in animals |
| 05/16/2013 | WO2013067591A1 Topical formulations for pain management |
| 05/16/2013 | WO2013067581A1 Cancer treatment |
| 05/16/2013 | WO2013067579A1 Adiposity-modulating molecules and uses therefor |
| 05/16/2013 | WO2013067578A1 Modulators of c3a receptors |
| 05/16/2013 | WO2013044044A3 Methods of treating fatty liver disease with helminth-derived glycan-containing compounds |
| 05/16/2013 | WO2013040068A3 Process for preparing synthetic prostacyclins |
| 05/16/2013 | WO2013024282A3 Inhibitor or down- regulator of the expression of one or both of tbk1 ikk-epsilon for use in the treatment of pi3kinase dependent cancer |
| 05/16/2013 | WO2013020108A3 Bile acid recycling inhibitors for treatment of pancreatitis |
| 05/16/2013 | WO2012177847A3 Methods of dissolving blood clots and the like |
| 05/16/2013 | WO2012175949A3 Method and apparatus for the production of an arabinoxylan-enriched preparation and other co-products |
| 05/16/2013 | WO2012173442A3 Composition containing bee venom phospholipase as an active ingredient treating prion disease |
| 05/16/2013 | WO2012167261A3 Compositions and methods for treating and preventing neointimal stenosis |
| 05/16/2013 | WO2012163937A3 Solid solutions of polyphenols |
| 05/16/2013 | WO2012054721A8 Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors |
| 05/16/2013 | WO2012051251A8 Methods of treating giardiasis |
| 05/16/2013 | WO2011123621A3 2' and 5' modified monomers and oligonucleotides |
| 05/16/2013 | US20130125259 Rna interference mediating small rna molecules |
| 05/16/2013 | US20130123741 Flexible sterile bag containing pharmaceutical products and diluant separately and method of making the same |
| 05/16/2013 | US20130123477 Tiacumicin Production |
| 05/16/2013 | US20130123370 Compositions and methods for treating Alzheimer's disease and related disorders and promoting a healthy nervous system |
| 05/16/2013 | US20130123368 Methods of reducing 15-f2t-isop levels in mammals |
| 05/16/2013 | US20130123366 Therapeutic Agents for the Treatment of Lymphoid Malignancies |
| 05/16/2013 | US20130123365 Use of fts and analogs to treat non-autoimmune-allergic and non-allergic inflammatory conditions |
| 05/16/2013 | US20130123364 N6-(1-iminoethyl)-l-lysine for regeneration of alveoli in lungs |
| 05/16/2013 | US20130123363 Medicinal agent for prevention and/or treatment of hepatocellular carcinoma |
| 05/16/2013 | US20130123362 Type a gelatin capsule containing pufa in free acid form |